MedTrace Logo

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

NCT06680544 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-11-08

No results posted yet for this study

Summary

Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

Conditions

  • Dermatophyte Infection

Interventions

DRUG

Voriconazole high dose

Oral voriconazole 200mg once a day for a maximum of 28 days

DRUG

Voriconazole low dose

Oral voriconazole 200mg twice a day for a maximum of 28 days

Sponsors & Collaborators

  • Sheikh Zayed Medical College

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2025-03-01
Completion
2025-03-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06680544 on ClinicalTrials.gov